Self-Immolative Linkers for Anti-EGFR Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugate (ADC) linkers, particularly cleavable and non-cleavable types, face instability issues, leading to premature drug dissociation from antibodies before reaching target cancer cells, affecting the efficacy and safety of cancer treatment.
Innovation Solution
Development of anti-epidermal growth factor receptor (EGFR) ADCs incorporating a self-immolative group and linkers such as O-substituted oximes or triazoles, which facilitate controlled release of the active agent by enzymatic cleavage, enhancing stability and targeting specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thiol-maleimide method is used to attach non-cleavable linkers to antibodies, then the drug can be attached to the antibody, but the antibody-drug conjugate becomes unstable and the drug may dissociate before reaching the target cell
Solution Approach 1:
The patent changes the chemical parameters of the linker by using different bonding mechanisms (thioether for non-cleavable, disulfide for cleavable, hydrazone for pH-sensitive) to achieve desired stability characteristics. This allows optimization of the linker's chemical properties to prevent premature drug dissociation while maintaining target cell delivery capability
Solution Approach 2:
The patent introduces enzyme-sensitive linkers that act as intermediaries between the antibody and drug. These linkers are designed to be stable in circulation but cleave specifically upon enzymatic action at the target site, thereby mediating the transition from stable conjugate to active drug release
2Ease of operation
If disulfide linkers are used to allow dissociation via thiol exchange reaction, then the drug can be released in the reducing cytosol environment, but the drug may dissociate from the antibody prior to reaching the target due to presence of thiols in blood
Solution Approach 1:
The patent applies local quality by designing linkers with different stability characteristics for different locations in the body. The linker is engineered to be stable in the oxidizing environment of blood circulation but labile in the reducing environment of the cytosol, thereby achieving location-specific drug release behavior
Solution Approach 2:
The patent inverts the conventional approach by using environment-sensitive chemistry in reverse: instead of making the linker inherently labile and relying on target cell uptake for stabilization, the linker is designed to be stable externally and only becomes labile upon specific enzymatic triggers at the target site
3Reliability
If non-cleavable linkers are used to maintain stability, then the drug remains attached to the antibody, but the active agent cannot be separated from the antibody and linker to exert therapeutic effect
Solution Approach 1:
The patent applies preliminary action by designing self-immolative linkers that automatically undergo intramolecular decomposition after enzymatic cleavage. This preliminary built-in mechanism ensures that once the linker is activated by the target enzyme, it automatically releases the drug without requiring additional cellular processes
Solution Approach 2:
The patent segments the linker into distinct functional modules: a stable attachment portion that binds to the antibody, a cleavable portion that responds to enzymatic triggers, and a self-immolative portion that facilitates drug release. This segmentation allows each module to perform its specific function optimally
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new ADCs demonstrate improved plasma stability and targeted drug delivery, increasing therapeutic efficacy while minimizing adverse reactions, as evidenced by extended half-life and specific cytotoxicity against EGFR-expressing cells.
Implementation Method 1
The linker ideally allows the drug to exhibit an effect on a target cancer cell, e.g., after being separated from the antibody (for example, by enzyme-mediated hydrolysis)
Implementation Method 2
A disulfide linker, which allows for dissociation via a thiol exchange reaction, relies in part on the uptake of an antibody-drug conjugate into a target cell and the exposure of the disulfide to the cytosol
Data Source
AI summary
In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor (“EGFR”) antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.